Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis Pauses Autoimmune Cell Therapy Studies After Deaths" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Новости GxP, European Biotechnology Magazine and Pharmaceutical Executive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1d ago.
Quick answers
Why is "Novartis Pauses Autoimmune Cell Therapy Studies After Deaths" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Novartis pauses eight CAR-T trials after three patient deaths Новости GxP · 3d ago
- Novartis: Three deaths put CAR-T expansion into autoimmune diseases on hold European Biotechnology Magazine · 3d ago
- Novartis and BMS Halt CAR-T Trials Pharmaceutical Executive · 3d ago
Topics
Related trends
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis has partnered with Alteogen in an agreement valued at up to $3.2 billion for subcutaneous drug delivery technology.
U.S. Stocks Rise as Treasury Selloff Pauses
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
Antithrombotic Therapy After TAVI
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.